1. Scrip
  2. >>Business
  3. >>Strategy

Portola: A Cardiovascular Boutique with Big Plans

 
• By Deborah Erickson

The founders of Bay Area start-up Portola Pharmaceuticals aim to leverage understanding of platelets, as well as their experiences at Cor Therapeutics and Millennium Pharmaceuticals. They intend to create an improved version of the blockbuster blood thinner Plavix. A key task for reaching that goal, they say, will be developing some new way to assay what's actually going on with platelets circulating in a patient's body at a given point in time.

The founders of Bay Area start-up Portola Pharmaceuticals Inc. think they know more than any other group about blood platelets, and how to use them for drug discovery and development. They could be right. All three—Charles Homcy, MD, David Phillips, PhD, and Robert Scarborough, PhD—were integral to the development of the acute anti-thrombotic drug eptifibatide (Integrilin) at Cor Therapeutics Inc. The injectable product generated $305.8 million in sales last year for Millennium Pharmaceuticals Inc. , which acquired Cor at the end of 2001 [See Deal].

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

More from Business

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.